Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Project Grant

McMaster University

$221,850.00

Short Term Anti-aRrhythmic Therapy for Post-Operative AF in Cardiac Surgery Patients: START-POAF Pilot Trial

FY 2022-23

Summary
Atrial fibrillation (AF) is the most common abnormal heart rhythm in the world. In patients who have cardiac surgery, new AF is found as an early complication in more than 1 out of every 4 surgeries. In the weeks and months after heart surgery, patients who have new AF take a medication called amiodarone to keep their heart in rhythm as it heals. If the heart goes back into AF, patients can have symptoms of heart racing, heart failure (fluid on the lungs) or stroke. AF is one of the most common reasons for unplanned visits to the hospital or emergency room following cardiac surgery. Although amiodarone is effective , it can have side effects like dizziness, nausea and slow heart rate. It may also damage the lungs, liver and thyroid gland. Many patients are not able to complete their full prescribed course after surgery. Therefore, it is crucial that we find the shortest possible length of treatment with amiodarone that will keep the heart in rhythm while minimizing the chance of side effects or organ damage. Amiodarone is different from most other drugs in that it builds up in body tissues and is released back into the blood stream for weeks after a patient stops taking it. The START-POAF trial will compare two different durations of amiodarone treatment: 1) in-hospital load only and 2) in-hospital load plus 4 weeks after discharge home. All participants in the trial will wear an electrocardiogram (ECG) monitor for 4 weeks after they are discharged home from surgery. We will compare the amount of AF seen on the ECG between the two groups. This randomized 'pilot' study is designed to test whether amiodarone dosing affects the amount of time patient's hearts will be in AF in the month following surgery. If it works, we will test it in a larger study. The larger randomized study will be designed to test the impacts of the two dosing regimens on the patient-important outcome of unplanned healthcare visits (urgent clinic, emergency room or repeat hospitalization)
Program
Project Grant
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
468578
Name
McIntyre William F
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Clinical
Prcname2
Clinical Investigation - D: Cardiovascular Systems
Projecttitle
Short Term Anti-aRrhythmic Therapy for Post-Operative AF in Cardiac Surgery Patients: START-POAF Pilot Trial
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$221,850
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Atrial Fibrillation; Cardiac Surgery; Heart Rhythm Monitoring; Pilot Randomized Controlled Trial
Abstract
Atrial fibrillation (AF) is the most common abnormal heart rhythm in the world. In patients who have cardiac surgery, new AF is found as an early complication in more than 1 out of every 4 surgeries. In the weeks and months after heart surgery, patients who have new AF take a medication called amiodarone to keep their heart in rhythm as it heals. If the heart goes back into AF, patients can have symptoms of heart racing, heart failure (fluid on the lungs) or stroke. AF is one of the most common reasons for unplanned visits to the hospital or emergency room following cardiac surgery. Although amiodarone is effective , it can have side effects like dizziness, nausea and slow heart rate. It may also damage the lungs, liver and thyroid gland. Many patients are not able to complete their full prescribed course after surgery. Therefore, it is crucial that we find the shortest possible length of treatment with amiodarone that will keep the heart in rhythm while minimizing the chance of side effects or organ damage. Amiodarone is different from most other drugs in that it builds up in body tissues and is released back into the blood stream for weeks after a patient stops taking it. The START-POAF trial will compare two different durations of amiodarone treatment: 1) in-hospital load only and 2) in-hospital load plus 4 weeks after discharge home. All participants in the trial will wear an electrocardiogram (ECG) monitor for 4 weeks after they are discharged home from surgery. We will compare the amount of AF seen on the ECG between the two groups. This randomized 'pilot' study is designed to test whether amiodarone dosing affects the amount of time patient's hearts will be in AF in the month following surgery. If it works, we will test it in a larger study. The larger randomized study will be designed to test the impacts of the two dosing regimens on the patient-important outcome of unplanned healthcare visits (urgent clinic, emergency room or repeat hospitalization)
Competitiondate
202209
Approvedterm2
2 yrs 0 mth
Pinamesdelim
McIntyre, William F
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $221,850~ $0~